BioCardia, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $58.0K | $477.0K | $1.4M | $1.0M | $145.0K | $710.0K |
| Cost of Revenue | — | — | — | — | — | $0 | $4.0K | $358.0K |
| Gross Profit | — | — | — | — | — | $1.0M | $141.0K | $352.0K |
| Gross Margin | — | — | — | — | — | 100.0% | 97.2% | 49.6% |
| Operating Expenses | ||||||||
| Research & Development | — | $5.0M | $4.4M | $7.7M | $8.8M | $8.6M | $9.8M | $8.6M |
| SG&A Expense | — | $3.3M | $3.7M | $4.4M | $4.4M | $5.1M | $5.9M | $6.0M |
| Operating Income | — | $-8.3M | $-8.0M | $-11.6M | $-11.9M | $-12.6M | $-15.5M | $-14.2M |
| Operating Margin | — | — | -13,794.8% | -2,441.1% | -880.3% | -1,244.3% | -10,709.7% | -2,001.8% |
| Interest Expense | — | — | — | — | — | $0 | $3.0K | $112.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-8.2M | $-7.9M | $-11.6M | $-11.9M | $-12.6M | $-15.0M | $-14.7M |
| Net Margin | — | — | -13,700.0% | -2,425.8% | -880.7% | -1,243.6% | -10,347.6% | -2,071.7% |
| EPS (Basic) | — | $-1.23 | $-1.45 | $-4.10 | $-0.34 | $-0.38 | $-0.74 | $-1.31 |
| EPS (Diluted) | — | — | — | — | — | $-0.38 | $-0.74 | $-1.31 |
| Shares Outstanding (Basic) | 10.9M | 6.7M | 5.5M | 2.8M | 35.4M | 33.8M | 32.6M | 13.7M |
| Shares Outstanding (Diluted) | 10.9M | 6.7M | 5.5M | 2.8M | 35.4M | 33.8M | 32.6M | 13.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |